의료진

스킵네비게이션

본문바로가기
주메뉴바로가기

기타
With 울산대학교병원

기타

의료진

기타의료진

종양내과민영주

진료분야폐암, 식도암, 두경부암, 흉선종양, 악성중피종

예약하기

진료일정 10월 선택됨 10월 11월

진료일정의 경우, 휴진 및 진료과의 사정으로 변경될 수 있으니 확인 후 내원해주시기 바랍니다.

이전달 다음달

민영주 진료일정표
날짜	1 수	2 목	3 금	4 토	5 일	6 월	7 화	8 수	9 목	10 금	11 토	12 일	13 월	14 화	15 수	16 목	17 금	18 토	19 일	20 월	21 화	22 수	23 목	24 금	25 토	26 일	27 월	28 화	29 수	30 목	31 금
오전
오후

진료 클리닉 휴진

학력
- 한양대학교 의학사
- 울산대학교 대학원 의학석사
- 인제대학교 대학원 의학박사
경력
- 서울아산병원 내과 전공의
- 서울아산병원 종양혈액내과 전임의
- 울산대학교병원 혈액종양내과 분과장 역임
- 울산대학교 의과대학 내과 교수
- 미국국립보건원(NIH)/미국국립암센터(NCI) 객원연구원
- 울산지역암센터 소장
- 임상시험센터 소장
- 내과 진료과장
- 교육수련부장
- 부산울산경남 종양연구회 회장
- 울산내과지회장
- 교육부원장
- 암생존자통합지지센터 소장
- 대한종양내과학회(KSMO)부회장
- 건강보험분쟁조정위원
- 대한두경부종양학회 상임이사
- 대한항암요법연구회 이사
소속학회
- 대한내과학회
- 대한암학회
- 대한종양내과학회
- 대한항암요법연구회
- 대한폐암학회
- 대한두경부종양학회
- 미국임상암학회(American Society of Clinical Oncology)
- 유럽종양내과학회(Euoropean Society of Medical Oncology)

CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Moon CH, Lee SJ, Lee HY, Dung LT, Cho WJ, Cha H, Park JW, Min YJ. Invest New Drugs. 2014 Jun;32(3):400-11
Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer. Cho EK, Park JY, Lee KH, Song HS, Min YJ, Kim YH, Kang JH. Cancer Chemother Pharmacol. 2014.73(1):9-16
Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma. Lee JC, Lee WH, Min YJ, Cha HJ, Han MW, Chang HW, Kim SA, Choi SH, Kim SW, Kim SY. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1203-11
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-label Study. Shin SH, Lee HS, Kim YS, Choi YJ, Kim SG, Kwon HC, Oh SY, Kang JH, Sohn CH, Lee SM, Baek JH, Min YJ, Kim C, Chung JS. Cancer Res Treat. 2014 Oct;46(4):331-8.
진행성 노인 폐암에 대한 항암요법 대한내과학회지. 2014;87(5): 537-541.(단독저자)
Rosmarinic acid potentiates ATRA-induced macrophage differentiation in acute promyelocytic leukemia NB4 cells. Heo SK, Noh EK, Yoon DJ, Jo JC, Koh S, Baek JH, Park JH, Min YJ, Kim H. Eur J Pharmacol. 2015 Jan 15;747:36-44
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K. Lung Cancer. 2015 Feb;87(2):148-54(책임저자)
Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea. Jo JC1, Baek JH, Koh SJ, Kim H, Min YJ, Lee BU, Kim BG, Jeong ID, Cho HR, Kim GY. Asia Pac J Clin Oncol. 2015 Dec 11(4):282-7
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells. Heo SK, Noh EK, Yoon DJ, Jo JC, Choi Y, Koh S, Baek JH, Park JH, Min YJ, Kim H. PLoS One. 2015 Jun 12;10(6):e0129853
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. J Clin Oncol.2015 Aug 20;33(24):2660-6
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Lancet Oncol. 2015 Aug;16(8):897-907.
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874
Tristetraprolin suppresses the EMT through the down-regulation of Twist1 and Snail1 in cancer cells. Yoon NA, Jo HG, Lee UH, Park JH, Yoon JE, Ryu J, Kang SS, Min YJ, Ju SA, Seo EH, Huh IY, Lee BJ, Park JW, Cho WJ. Oncotarget. 2016 Feb 23;7(8):8931-43. doi: 10.18632/oncotarget.7094.
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Oncotarget. 2016 Apr 21. doi: 10.18632/oncotarget.8904. [Epub ahead of print
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. Han JY, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS. Cancer Res Treat. 2016 May 3. doi: 10.4143/crt.2016.058. [Epub ahead of print]
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. Park K, Lee JS, Han JY, Lee KH, Kim JH, Cho EK, Cho JY, Min YJ, Kim JS, Kim DW. J Thorac Oncol. 2016 Apr;11(4 Suppl):S113. doi: 10.1016/S1556-0864(16)30243-X. Epub 2016 Apr 15.
Metastatic prostate cancer initially presenting as chylothorax: A case report. Yang YJ, Seo M, Jeon HJ, Noh JH, Park SH, Choi Y, Jo JC, Baek JH, Koh SJ, Kim H, Min YJ. Mol Clin Oncol. 2016 Jun;4(6):1009-1012.
Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. Heo SK, Noh EK, Gwon GD, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. Eur J Pharmacol. 2016 Jul 8;789:280-290
LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells. Heo SK, Noh EK, Gwon GD, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. PLoS One. 2016 Nov 11;11(11):e0166589
Attitudes toward participating in Phase I clinical trials: an investigation with patient-family-physician triads. Shin DW, Cho J, Kim SY, Yang HK, Cho B, Shin DB, Chun MS, Min YJ, Kim YW, Park JH. Jpn J Clin Oncol. 2016 Dec;46(12):1095-110
Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells. Heo SK, Noh EK, Kim JY, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. Eur J Pharmacol. 2017 Jun 5;804:52-5
Cross-cultural application of the Korean version of the EORTC QLQ-ELD14 questionnaire for elderly patients with cancer. Goo AJ, Shin DW, Yang HK, Park JH, Kim SY, Shin JY, Kim YA, Kim C, Hong NS, Min YJ, Park K. J Geriatr Oncol. 2017 Jul;8(4):271-276
Realities of KRAS-mutated non-small cell lung cancer. Min YJ. Korean J Intern Med. 2017 May;32(3):442
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. J Clin Oncol. 2017 Aug 10;35(23):2613-261
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Heo SK, Noh EK, Kim JY, Jeong YK, Jo JC, Choi Y, Koh S, Baek JH, Min YJ, Kim H. Sci Rep. 2017 Nov 10;7(1):15278. doi: 10.1038/s41598-017-15492-5
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ. Br J Cancer. 2018 Mar 6;118(5):648-653.
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01).Ku BM, Heo MH, Kim JH, Cho BC, Cho EK, Min YJ, Lee KH, Sun JM, Lee SH, Ahn JS, Park K, Kim TJ, Lee HY, Kim H, Lee KJ, Ahn MJ. J Pathol Transl Med. 2018 May;52(3):148-156.
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. JAMA Oncol. 2018 Sep 1;4(9):1189-1197
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K. Lung Cancer. 2018 Aug;122:234-242
Rhein augments ATRA-induced differentiation of acute promyelocytic leukemia cells. Heo SK, Noh EK, Kim JY, Jegal S, Jeong Y, Cheon J, Koh S, Baek JH, Min YJ, Choi Y, Jo JC. Phytomedicine. 2018 Oct 1;49:66-74
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. N Engl J Med. 2018 Nov 22;379(21):2040-205
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee SH, Ahn JS, Cheon J, Min YJ, Park SH, Park K, Ahn MJ, Shin EC. Clin Cancer Res2019 Apr 1;25(7):2144-2154
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression. Heo SK, Noh EK, Jeong YK, Ju LJ, Sung JY, Yu HM, Cheon J, Koh S, Min YJ, Choi Y, Jo JC. Tumour Biol. 2019 May;41(5):1010428319848612
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, Cho JY, An HJ, Kim HG, Lee KH, Kim BS, Jang IJ, Yoon S, Han O, Noh YS, Hong KY, Park K. Lung Cancer. 2019 Sep;135:66-72
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Lancet Oncol. 2019 Dec;20(12):1681-1690
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Lancet Oncol. 2019 Dec;20(12):1655-1669
Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, Min YJ, Kim SW, Park K, Lee SS, Kim S, Kim HR, Cho BC; Korean Lung Cancer Consortium (KLCC) PLoS One. 2019 Nov 25;14(11):e0224379
CD45 dim CD34 + CD38 - CD133 + cells have the potential as leukemic stem cells in acute myeloid leukemia Heo SK, Noh EK, Ju LJ, Sung JY, Jeong YK, Cheon J, Koh SJ, Min YJ, Choi Y, Jo JC. BMC Cancer. 2020 Apr 6;20(1):285
Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. Cheon J, Lee YJ, Jo JC, Kweon K, Koh S, Min YJ, Park SH, Lee SH, Kim HJ, Choi Y Support Care Cancer. 2020 Jun 17. doi: 10.1007/s00520-020-05572-0. Online ahead of print
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. Hong MH, Heo SG, Lee YG, Kim HS, Park KU, Kim HG, Ko YH, Chung IJ, Min YJ, Kim MK, Kim KR, Yoo J, Kim TM, Kim HR, Cho BC.Cancer. 2020 Aug 4. doi: 10.1002/cncr.33123. Online ahead of print
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. N Engl J Med. 2020 Nov 19;383(21):2018-2029

울산대학교병원

울산대학교병원 주메뉴

With 울산대학교병원

의료진

종양내과민영주

상세정보

학력

경력

소속학회

논문

언론

영상